Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
Raymund R Razonable, Colin Pawlowski, John C O'horo, Lori L Arndt, Richard Arndt, Dennis M Bierle, Molly Destro Borgen, Sara N Hanson, Michelle C Hedin, Patrick Lenehan, Arjun Puranik, Maria T Seville, Leigh L Speicher, Sidna M Tulledge-Scheitel, A J Venkatakrishnan, Caroline G Wilker, Andrew D Badley, Ravindra Ganesh
EClinicalMedicine, doi:10.1016/j.eclinm.2021.101102
Background: Real-world clinical data to support the use of casirivimabÀimdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimabÀimdevimab treatment of mild to moderate COVID-19. Methods: A retrospective cohort of 696 patients who received casirivimabÀimdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion. Findings: The median age of the antibody-treated cohort was 63 years (interquartile range, 52À71); 45¢5% were 65 years old; 51.4% were female. High-risk characteristics were hypertension (52.4%), body mass index 35 (31.0%), diabetes mellitus (24.6%), chronic lung disease (22.1%), chronic renal disease (11.4%), congestive heart failure (6.6%), and compromised immune function (6.7%). Compared to the propensitymatched untreated control, patients who received casirivimabÀimdevimab had significantly lower all-cause hospitalization rates at day 14 (1.3% vs 3.3%; Absolute Difference: 2.0%; 95% confidence interval (CI): 0.5À3.7%), day 21 (1.3% vs 4.2%; Absolute Difference: 2.9%; 95% CI: 1.2À4.7%), and day 28 (1.6% vs 4.8%; Absolute Difference: 3.2%; 95% CI: 1.4À5.1%). Rates of intensive care unit admission and mortality at days 14, 21 and 28 were similarly low for antibody-treated and untreated groups. Interpretation: Among high-risk patients with mild to moderate COVID-19, casirivimabÀimdevimab treatment was associated with a significantly lower rate of hospitalization. Funding: Mayo Clinic.
Funding
Mayo Clinic
Contributors Concept and Design: Razonable, Pawlowski, Ganesh Acquisition, Analysis, or Interpretation of Data: Razonable, Pawlowski, Lenehan, Puranik, Venkatakrishnan, O'Horo, Badley, Ganesh Drafting of the Manuscript:
Supplementary materials Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2021.101102.
References
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -final report, N Engl J Med
Bhimraj, Morgan, Schumaker, Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19
Caliendo, Kopeinig, Some practical guidance for the implementation of propensity score matching, J Econ Surv
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med
Crane, Ganesh, Post, Jacobson, Telemedicine consultations and followup of patients with COVID-19, Mayo Clin Proc
Davidson-Pilon, Kalderstam, Zivich, CamDavidsonPilon/lifelines: v0. 21.3. Zenodo
Ganesh, Salonen, Bhuiyan, Managing patients in the COVID-19 pandemic: a virtual multidisciplinary approach, Mayo Clinic Proc: Innovat, Qual Outcomes
Garcia-Vidal, Cozar-Llisto, Meira, Trends in mortality of hospitalised COVID-19 patients: a single centre observational cohort study from Spain, Lancet Reg Health Eur
Group, Horby, Lim, Dexamethasone in hospitalized patients with Covid-19 -preliminary report, N Engl J Med
Horwitz, Jones, Cerfolio, Trends in COVID-19 risk-adjusted mortality rates, J Hosp Med
Hosmer, Lemeshow, May, Applied survival analysis: regression modeling of time-to-event data
Huang, Yang, Xu, Xu, Liu, Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19, Acta Pharmacol Sin
Nih, Anti, SARS-CoV-2 monoclonal antibodies
O'horo, Cerhan, Cahn, Outcomes of COVID-19 with the mayo clinic model of care and research
Razonable, Aloia, Anderson, A framework for outpatient infusion of anti-spike monoclonal antibodies to high-risk patients with mild to moderate coronavirus disease-19: the mayo clinic model
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Tian, Schuemie, Suchard, Evaluating large-scale propensity score performance through real-world and synthetic data experiments, Int J Epidemiol
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
{ 'indexed': {'date-parts': [[2023, 5, 20]], 'date-time': '2023-05-20T05:19:10Z', 'timestamp': 1684559950727},
'reference-count': 23,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2021, 10, 1]],
'date-time': '2021-10-01T00:00:00Z',
'timestamp': 1633046400000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2021, 8, 12]],
'date-time': '2021-08-12T00:00:00Z',
'timestamp': 1628726400000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'funder': [ {'DOI': '10.13039/100007048', 'name': 'Mayo Clinic', 'doi-asserted-by': 'publisher'},
{'DOI': '10.13039/100004337', 'name': 'Roche', 'doi-asserted-by': 'publisher'},
{'DOI': '10.13039/100005564', 'name': 'Gilead Sciences', 'doi-asserted-by': 'publisher'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2021, 10]]},
'DOI': '10.1016/j.eclinm.2021.101102',
'type': 'journal-article',
'created': {'date-parts': [[2021, 8, 30]], 'date-time': '2021-08-30T11:00:58Z', 'timestamp': 1630321258000},
'page': '101102',
'source': 'Crossref',
'is-referenced-by-count': 93,
'title': 'Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among '
'high-risk patients with mild to moderate coronavirus disease-19',
'prefix': '10.1016',
'volume': '40',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-5248-0227',
'authenticated-orcid': False,
'given': 'Raymund R.',
'family': 'Razonable',
'sequence': 'first',
'affiliation': []},
{'given': 'Colin', 'family': 'Pawlowski', 'sequence': 'additional', 'affiliation': []},
{'given': 'John C.', 'family': "O'Horo", 'sequence': 'additional', 'affiliation': []},
{'given': 'Lori L.', 'family': 'Arndt', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-4723-689X',
'authenticated-orcid': False,
'given': 'Richard',
'family': 'Arndt',
'sequence': 'additional',
'affiliation': []},
{'given': 'Dennis M.', 'family': 'Bierle', 'sequence': 'additional', 'affiliation': []},
{'given': 'Molly Destro', 'family': 'Borgen', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-2517-638X',
'authenticated-orcid': False,
'given': 'Sara N.',
'family': 'Hanson',
'sequence': 'additional',
'affiliation': []},
{'given': 'Michelle C.', 'family': 'Hedin', 'sequence': 'additional', 'affiliation': []},
{'given': 'Patrick', 'family': 'Lenehan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Arjun', 'family': 'Puranik', 'sequence': 'additional', 'affiliation': []},
{'given': 'Maria T', 'family': 'Seville', 'sequence': 'additional', 'affiliation': []},
{'given': 'Leigh L.', 'family': 'Speicher', 'sequence': 'additional', 'affiliation': []},
{ 'given': 'Sidna M.',
'family': 'Tulledge-Scheitel',
'sequence': 'additional',
'affiliation': []},
{'given': 'AJ', 'family': 'Venkatakrishnan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Caroline G.', 'family': 'Wilker', 'sequence': 'additional', 'affiliation': []},
{'given': 'Andrew D.', 'family': 'Badley', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ravindra', 'family': 'Ganesh', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/j.eclinm.2021.101102_bib0001',
'article-title': 'An EUA for bamlanivimab-a monoclonal antibody for COVID-19',
'year': '2020',
'journal-title': 'JAMA'},
{ 'issue': '1614',
'key': '10.1016/j.eclinm.2021.101102_bib0002',
'first-page': '201',
'article-title': 'An EUA for casirivimab and imdevimab for COVID-19',
'volume': '62',
'year': '2020',
'journal-title': 'Med Lett Drugs Ther'},
{ 'issue': '1621',
'key': '10.1016/j.eclinm.2021.101102_bib0003',
'first-page': '49',
'article-title': 'An EUA for bamlanivimab and etesevimab for COVID-19',
'volume': '63',
'year': '2021',
'journal-title': 'Med Lett Drugs Ther'},
{ 'issue': '9',
'key': '10.1016/j.eclinm.2021.101102_bib0004',
'doi-asserted-by': 'crossref',
'first-page': '1141',
'DOI': '10.1038/s41401-020-0485-4',
'article-title': 'Structural and functional properties of SARS-CoV-2 spike protein: '
'potential antivirus drug development for COVID-19',
'volume': '41',
'author': 'Huang',
'year': '2020',
'journal-title': 'Acta Pharmacol Sin'},
{ 'issue': '3',
'key': '10.1016/j.eclinm.2021.101102_bib0005',
'doi-asserted-by': 'crossref',
'first-page': '238',
'DOI': '10.1056/NEJMoa2035002',
'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with '
'Covid-19',
'volume': '384',
'author': 'Weinreich',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/j.eclinm.2021.101102_bib0006',
'unstructured': 'Bhimraj A, Morgan R, Schumaker AH, et\xa0al. Infectious diseases society '
'of America guidelines on the treatment and management of patients with '
'COVID-19. Available at: '
'https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. '
'Accessed 05/10/ 2021.'},
{ 'key': '10.1016/j.eclinm.2021.101102_bib0007',
'unstructured': 'NIH. Anti-SARS-CoV-2 monoclonal antibodies. Available at: '
'https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/. '
'Accessed May 10, 2021.'},
{ 'key': '10.1016/j.eclinm.2021.101102_bib0008',
'series-title': 'A framework for outpatient infusion of anti-spike monoclonal antibodies '
'to high-risk patients with mild to moderate coronavirus disease-19: the '
'mayo clinic model',
'author': 'Razonable',
'year': '2021'},
{ 'issue': '1',
'key': '10.1016/j.eclinm.2021.101102_bib0009',
'doi-asserted-by': 'crossref',
'first-page': '31',
'DOI': '10.1111/j.1467-6419.2007.00527.x',
'article-title': 'Some practical guidance for the implementation of propensity score '
'matching',
'volume': '22',
'author': 'Caliendo',
'year': '2008',
'journal-title': 'J Econ Surv'},
{ 'issue': '6',
'key': '10.1016/j.eclinm.2021.101102_bib0010',
'doi-asserted-by': 'crossref',
'first-page': '2005',
'DOI': '10.1093/ije/dyy120',
'article-title': 'Evaluating large-scale propensity score performance through real-world '
'and synthetic data experiments',
'volume': '47',
'author': 'Tian',
'year': '2018',
'journal-title': 'Int J Epidemiol'},
{ 'key': '10.1016/j.eclinm.2021.101102_bib0011',
'series-title': 'Applied survival analysis: regression modeling of time-to-event data',
'author': 'Hosmer',
'year': '2008'},
{ 'key': '10.1016/j.eclinm.2021.101102_bib0012',
'unstructured': 'Davidson-Pilon C, Kalderstam J, Zivich P, et\xa0al. '
'CamDavidsonPilon/lifelines: v0. 21.3. Zenodo 2019.'},
{ 'issue': '20',
'key': '10.1016/j.eclinm.2021.101102_bib0013',
'doi-asserted-by': 'crossref',
'first-page': '2052',
'DOI': '10.1001/jama.2020.6775',
'article-title': 'Presenting characteristics, comorbidities, and outcomes among 5700 '
'patients hospitalized with COVID-19 in the New York City area',
'volume': '323',
'author': 'Richardson',
'year': '2020',
'journal-title': 'JAMA'},
{ 'issue': '10229',
'key': '10.1016/j.eclinm.2021.101102_bib0014',
'doi-asserted-by': 'crossref',
'first-page': '1054',
'DOI': '10.1016/S0140-6736(20)30566-3',
'article-title': 'Clinical course and risk factors for mortality of adult inpatients with '
'COVID-19 in Wuhan, China: a retrospective cohort study',
'volume': '395',
'author': 'Zhou',
'year': '2020',
'journal-title': 'Lancet'},
{ 'issue': '3',
'key': '10.1016/j.eclinm.2021.101102_bib0015',
'doi-asserted-by': 'crossref',
'first-page': '229',
'DOI': '10.1056/NEJMoa2029849',
'article-title': 'SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19',
'volume': '384',
'author': 'Chen',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'issue': '9s',
'key': '10.1016/j.eclinm.2021.101102_bib0016',
'article-title': 'Telemedicine consultations and follow-up of patients with COVID-19',
'volume': '95',
'author': 'Crane',
'year': '2020',
'journal-title': 'Mayo Clin Proc'},
{ 'issue': '1',
'key': '10.1016/j.eclinm.2021.101102_bib0017',
'first-page': '118',
'article-title': 'Managing patients in the COVID-19 pandemic: a virtual multidisciplinary '
'approach',
'volume': '5',
'author': 'Ganesh',
'year': '2021',
'journal-title': 'Mayo Clinic Proc: Innovat, Qual Outcomes'},
{ 'key': '10.1016/j.eclinm.2021.101102_bib0018',
'series-title': 'Outcomes of COVID-19 with the mayo clinic model of care and research',
'author': "O'Horo",
'year': '2020'},
{ 'issue': '19',
'key': '10.1016/j.eclinm.2021.101102_bib0019',
'doi-asserted-by': 'crossref',
'first-page': '1813',
'DOI': '10.1056/NEJMoa2007764',
'article-title': 'Remdesivir for the treatment of Covid-19 - final report',
'volume': '383',
'author': 'Beigel',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'issue': '8',
'key': '10.1016/j.eclinm.2021.101102_bib0020',
'first-page': '693',
'article-title': 'Dexamethasone in hospitalized patients with Covid-19 - preliminary '
'report',
'volume': '384',
'author': 'Group',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/j.eclinm.2021.101102_bib0021',
'article-title': 'Trends in mortality of hospitalised COVID-19 patients: a single centre '
'observational cohort study from Spain',
'volume': '3',
'author': 'Garcia-Vidal',
'year': '2021',
'journal-title': 'Lancet Reg Health Eur'},
{ 'issue': '2',
'key': '10.1016/j.eclinm.2021.101102_bib0022',
'doi-asserted-by': 'crossref',
'first-page': '90',
'DOI': '10.12788/jhm.3552',
'article-title': 'Trends in COVID-19 risk-adjusted mortality rates',
'volume': '16',
'author': 'Horwitz',
'year': '2021',
'journal-title': 'J Hosp Med'},
{ 'key': '10.1016/j.eclinm.2021.101102_bib0023',
'unstructured': 'Medicine JHU. Coronavirus resource center. Available at: '
'https://coronavirus.jhu.edu/. Accessed 06/02/ 2021.'}],
'container-title': 'EClinicalMedicine',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2589537021003825?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S2589537021003825?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2021, 10, 25]],
'date-time': '2021-10-25T21:24:45Z',
'timestamp': 1635197085000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2589537021003825'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 10]]},
'references-count': 23,
'alternative-id': ['S2589537021003825'],
'URL': 'http://dx.doi.org/10.1016/j.eclinm.2021.101102',
'relation': {},
'ISSN': ['2589-5370'],
'subject': ['General Medicine'],
'container-title-short': 'EClinicalMedicine',
'published': {'date-parts': [[2021, 10]]},
'article-number': '101102'}
